Q2 EPS Estimates for Zimmer Biomet Lowered by Zacks Research

Zimmer Biomet Holdings, Inc. (NYSE:ZBHFree Report) – Investment analysts at Zacks Research reduced their Q2 2025 earnings per share estimates for shares of Zimmer Biomet in a report released on Wednesday, June 25th. Zacks Research analyst R. Department now expects that the medical equipment provider will post earnings per share of $1.97 for the quarter, down from their prior estimate of $1.98. The consensus estimate for Zimmer Biomet’s current full-year earnings is $8.22 per share. Zacks Research also issued estimates for Zimmer Biomet’s FY2025 earnings at $7.91 EPS, FY2026 earnings at $8.05 EPS and FY2027 earnings at $8.59 EPS.

Zimmer Biomet (NYSE:ZBHGet Free Report) last posted its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.04. The business had revenue of $1.91 billion during the quarter, compared to analyst estimates of $1.89 billion. Zimmer Biomet had a return on equity of 12.73% and a net margin of 11.86%. The company’s quarterly revenue was up 1.1% compared to the same quarter last year. During the same quarter last year, the company earned $1.94 EPS.

Several other brokerages have also commented on ZBH. Stifel Nicolaus set a $115.00 price objective on Zimmer Biomet and gave the stock a “buy” rating in a report on Tuesday, May 6th. JMP Securities cut their price objective on Zimmer Biomet from $140.00 to $125.00 and set a “market outperform” rating for the company in a report on Wednesday, May 7th. Robert W. Baird cut their price target on Zimmer Biomet from $130.00 to $115.00 and set an “outperform” rating for the company in a report on Tuesday, May 6th. Morgan Stanley reduced their price target on Zimmer Biomet from $115.00 to $95.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 6th. Finally, Truist Financial set a $101.00 price target on Zimmer Biomet in a research report on Tuesday, May 6th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, Zimmer Biomet has an average rating of “Hold” and a consensus price target of $111.53.

Check Out Our Latest Analysis on ZBH

Zimmer Biomet Stock Performance

Shares of ZBH opened at $91.46 on Friday. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.44 and a quick ratio of 1.46. Zimmer Biomet has a one year low of $89.22 and a one year high of $116.71. The firm has a market capitalization of $18.10 billion, a P/E ratio of 20.23, a PEG ratio of 2.12 and a beta of 0.72. The business has a fifty day moving average of $94.65 and a 200 day moving average of $102.26.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Thursday, June 26th will be given a $0.24 dividend. The ex-dividend date of this dividend is Thursday, June 26th. This represents a $0.96 annualized dividend and a dividend yield of 1.05%. Zimmer Biomet’s payout ratio is 21.24%.

Insider Activity

In related news, insider Sang Yi sold 1,000 shares of the business’s stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total value of $95,000.00. Following the sale, the insider now directly owns 20,424 shares in the company, valued at approximately $1,940,280. The trade was a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.39% of the company’s stock.

Institutional Investors Weigh In On Zimmer Biomet

A number of hedge funds have recently made changes to their positions in ZBH. Brighton Jones LLC purchased a new stake in shares of Zimmer Biomet in the fourth quarter worth about $204,000. Private Advisor Group LLC raised its position in Zimmer Biomet by 25.5% during the fourth quarter. Private Advisor Group LLC now owns 13,879 shares of the medical equipment provider’s stock valued at $1,466,000 after purchasing an additional 2,822 shares during the period. Equity Investment Corp grew its stake in shares of Zimmer Biomet by 57.2% during the fourth quarter. Equity Investment Corp now owns 1,021,062 shares of the medical equipment provider’s stock valued at $107,855,000 after buying an additional 371,653 shares during the last quarter. Mn Services Vermogensbeheer B.V. grew its stake in shares of Zimmer Biomet by 1.6% during the fourth quarter. Mn Services Vermogensbeheer B.V. now owns 81,500 shares of the medical equipment provider’s stock valued at $8,609,000 after buying an additional 1,300 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. grew its stake in shares of Zimmer Biomet by 47.1% during the fourth quarter. Oppenheimer Asset Management Inc. now owns 10,251 shares of the medical equipment provider’s stock valued at $1,083,000 after buying an additional 3,281 shares during the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Company Profile

(Get Free Report)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Featured Articles

Earnings History and Estimates for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.